Ginkgo Bioworks Holdings, Inc. (DNA) announced on Tuesday a collaboration with Carnegie Mellon University, securing a contract worth up to $9.4 million. This agreement entails the development of bioelectronic cell-based devices designed for the diagnosis and treatment of hormone disorders.
The initiative, titled "Biointegrated Implantable Systems for Cell-based Sensing and Therapy," will focus on the creation of implantable bioelectronic devices. These devices will utilize engineered cells to either produce therapeutic molecules on demand or measure disease biomarkers in real time.
According to the contract, Ginkgo will leverage its expertise in mammalian cell engineering and induced pluripotent stem cell technology. The aim is to engineer cells capable of producing and delivering therapeutic molecules as well as monitoring disease status effectively.
As of now, Ginkgo's stock is trading at $9.28, reflecting a decline of 1.59 percent on the New York Stock Exchange.
